CSBR

Champions Oncology Inc

Add to Watchlist

Advanced Chart

7.845

-0.185(-2.304%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.445

Open

8.445

VWAP

7.97

Vol

97.11K

Mkt Cap

108.47M

Low

7.500

Amount

774.30K

EV/EBITDA(TTM)

12.79

Total Shares

13.59M

107.81M

EV/OCF(TTM)

P/S(TTM)

1.91

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

15.53M

+15.1%

0.080

+60%

14.67M

+4.3%

0.060

-45.45%

12.01M

-14.2%

-0.200

-2100%

Estimates Revision

The market is revising No Change the revenue expectations for Champions Oncology, Inc. (CSBR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -0.32%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-0.32%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Champions Oncology Inc (CSBR.O) is 133.83, compared to its 5-year average forward P/E of 45.86. For a more detailed relative valuation and DCF analysis to assess Champions Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

45.86

Current PE

133.83

Overvalued PE

98.09

Undervalued PE

-6.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

22.62

Current EV/EBITDA

43.67

Overvalued EV/EBITDA

73.10

Undervalued EV/EBITDA

-27.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.96

Current PS

1.84

Overvalued PS

2.71

Undervalued PS

1.21

Financials

Annual

Quarterly

FY2025Q3

YoY :

+41.77%

17.04M

Total Revenue

FY2025Q3

YoY :

-274.58%

4.50M

Operating Profit

FY2025Q3

YoY :

-277.67%

4.50M

Net Income after Tax

FY2025Q3

YoY :

-263.16%

0.31

EPS - Diluted

FY2025Q3

YoY :

-142.87%

448.00K

Free Cash Flow

FY2025Q3

YoY :

+76.28%

61.17

Gross Profit Margin - %

FY2025Q3

YoY :

-83.44%

-2.26

FCF Margin - %

FY2025Q3

YoY :

-225.32%

26.38

Net Margin - %

FY2025Q3

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CSBR News & Events

Events Timeline

2025-07-18 (ET)

2025-07-18

08:33:03

Champions Oncology appoints Rob Brainin as CEO

2025-07-08 (ET)

2025-07-08

08:50:51

Champions Oncology announces launch of radiopharmaceutical services platform

2025-04-28 (ET)

2025-04-28

09:47:24

Champions Oncology obtains radioactive materials license

News

2.0

04-13Yahoo Finance

Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year

4.0

03-12Business Insider

Champions Oncology price target raised to $12 from $8 at Craig-Hallum

3.0

03-04NASDAQ.COM

CHAMPIONS ONCOLOGY Earnings Preview: Recent $CSBR Insider Trading, Hedge Fund Activity, and More

People Also Watch

Core Molding Technologies Inc

Ocean Power Technologies Inc

SB Financial Group Inc

Lument Finance Trust Inc

FAQ

What is Champions Oncology Inc (CSBR) stock price today?

The current price of CSBR is 7.845 USD — it has decreased -2.3 % in the last trading day.

CSBR

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CSBR News & Events

Events Timeline

News

People Also Watch

FAQ

What is Champions Oncology Inc (CSBR) stock price today?

What is Champions Oncology Inc (CSBR)'s business?

What is the price predicton of CSBR Stock?

What is Champions Oncology Inc (CSBR)'s revenue for the last quarter?

What is Champions Oncology Inc (CSBR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Champions Oncology Inc (CSBR)'s fundamentals?

How many employees does Champions Oncology Inc (CSBR). have?

What is Champions Oncology Inc (CSBR) market cap?